<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146166">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01740986</url>
  </required_header>
  <id_info>
    <org_study_id>SA09012-P2</org_study_id>
    <nct_id>NCT01740986</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of SA09012 in Asthma</brief_title>
  <official_title>Double Blinded, Randomized, Placebo Controlled, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy, Dose-response and Safety of SA09012 in Bronchial Asthma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SamA Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SamA Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Study to Evaluate the Efficacy, Dose-response and Safety of SA09012 in Bronchial
      Asthma Patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean change from baseline of PEF(Peak Expiratory Flow)at week 6</measure>
    <time_frame>6 week treatment period</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in FEV1 at week 6</measure>
    <time_frame>6 week treatment period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in ACT(Asthma Control Test) at week 6</measure>
    <time_frame>6 week treatment period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment(Comparison of the adverse event profiles throughout the course of the study)</measure>
    <time_frame>6 week treatment period</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Mild to Moderate Bronchial Asthma</condition>
  <arm_group>
    <arm_group_label>SA09012 Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SA09012 High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SA09012 Low dose</intervention_name>
    <description>Tablet, b.i.d</description>
    <arm_group_label>SA09012 Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SA09012 High dose</intervention_name>
    <description>Tablet, b.i.d</description>
    <arm_group_label>SA09012 High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, b.i.d</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis or presence of asthma the previous quarter of the screening visit

          -  FEV1 or PEF between 60% and 85% of the predicted normal value at screening or within
             the 3 months of the screening visit

          -  Having signed an informed consent

        Exclusion Criteria:

          -  Patient who has severe asthma

          -  Patient who has any significant medical condition that might compromise patient
             safety, interfere with evaluation or preclude completion of the study other
             protocol-defined inclusion/exclusion criteria may apply

          -  Patient with an AST or ALT &gt; 2x ULN (upper limit of normal) in the screening visit

          -  Patient with more than 10 pack year of cigarettes history
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Kyoon Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul ST. Mary's Hospital of the Catholic University of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young Kyoon Kim</last_name>
    <email>youngkim@catholic.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital of the Catholic university of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Kyoon Kim</last_name>
      <email>youngkim@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Young Kyoon Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 5, 2012</lastchanged_date>
  <firstreceived_date>November 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
